Cardiovascular risk in women with pre-eclampsia
Dosing Protocol Research-use protocol examples with verified 100 mg vial conversions
In December 2025, the Food and Drug Administration (FDA) approved an oral pill form of Wegovy for weight loss, and in April 2026 approved the once-daily oral GLP-1 drug Foundayo (orforglipron) also for weight loss
Connectivity map identifies luteolin as a treatment option of ischemic stroke by inhibiting MMP9 and activation of the PI3K/Akt signaling pathway
Safety, side effects, and who should be cautious Retatrutide GLP 3 works on powerful metabolic pathways, so side effects and contraindications must be taken seriously
By contrast, preclinical in vivo and in vitro studies both indicate that incretin receptor agonism can attenuate fibrogenic signalling in models of kidney disorders, and thus the positive clinical trial data on kidney function outcome measures may, in part, be mediated by inhibition of fibrosis